Recent advancements in drug development could significantly impact the fight against sleeping sickness, a disease caused by the Trypanosoma parasite.
The global health community has set a target to eliminate this disease by 2030, and this new drug may play a crucial role in achieving that objective.
As implementation strategies are considered, the capacity for widespread distribution and integration into existing health systems will be critical for success.